A Phase 3 interventional study of Dexycu and Placebo/Vehicle in Cataract, sponsored by EyePoint Pharmaceuticals, Inc.. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.
Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.
Among the 34 studies testing dexamethasone in Cataract, this one is the 31st largest by enrollment, is one of 6 that started in 2022, is one of 9 in phase 3, and was the 27th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 10 · Phase 4 18
First in 2004; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 50 across the 34 interventional studies. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 34 have an industry lead sponsor. The 10 most frequent:
EyePoint Pharmaceuticals, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
EyePoint Pharmaceuticals, Inc. has 4 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing dexamethasone in Cataract, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
Drug: Dexycu
Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
Other: Placebo/Vehicle
103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
Proportion of subjects with absence of ocular pain (ie, score of '0') in the study eye at Day 8
Time frame: Day 8
Proportion of subjects with absence of ocular pain in the study eye at Days 1, 3, 15, and 30
Time frame: Days 1, 3, 15, and 30
Mean ocular pain scores in the study eye
Numerical Ocular Pain Scale from 0-10 with 0 being no pain and 10 being most severe
Time frame: Days 1, 3, 15, and 30
Proportion of subjects with absence of cells in the AC of the study eye
Time frame: Days 1, 3, 15, and 30
Proportion of subjects with absence of flare in the AC of the study eye
Time frame: Days 1, 3, 15, and 30
Mean AC cell score in the study eye
AC count by Slit Lamp Biomicroscopy with 0 being none and 4 being most severe
Time frame: Days 1, 3, 15, and 30
Mean AC flare score in the study eye
AC flare by Slit Lamp Biomicroscopy with 0 being absent and 4 being strong intensity
Time frame: Days 1, 3, 15, and 30
Rates of ocular (study eye and fellow eye) and non-ocular TEAEs
Time frame: up to day 30
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2022; primary completion for Sep 2023, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
EyePoint Pharmaceuticals, Inc.